Intravitreal Bevacizumab Improves Trabeculectomy Survival at 3 Years: Long-term Follow-up from the Bevacizumab in Trabeculectomy Study.
OphthalmologyMay 14, 2026 (epub)
Clinical ResearchOphthalmology
John Landers, Sean Mullany, Mark M Hassall et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial assessed the impact of a single intraoperative dose of intravitreal bevacizumab on trabeculectomy success over three years in patients with glaucoma. The study found that at 36 months, the bevacizumab group had significantly higher rates of surgical success, with a hazard ratio for complete success of 0.17 and for qualified success of 0.07.
Key findings
- At 36 months, complete success was significantly higher in the bevacizumab group (hazard ratio = 0.17, P = 0.002).
- Qualified success was also significantly improved in the bevacizumab cohort (hazard ratio = 0.07, P = 0.03).
- The placebo group required more topical therapy at multiple follow-up points, including 3 months (P = 0.008) and 36 months (P < 0.005).
Why it matters
The findings suggest that intravitreal bevacizumab may enhance the long-term success of trabeculectomy, potentially reducing the need for postoperative medications in glaucoma patients. This could influence surgical decision-making and patient management strategies.